

Benoit J Arsenault

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8254008/benoit-j-arsenault-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

115
papers

5,539
citations

36
h-index

73
g-index

133
ext. papers

7,031
ext. citations

6
avg, IF

5.38
L-index

#	Paper	IF	Citations
115	The promise and challenges of RNA-targeted therapeutics in preventive cardiology.. <i>European Heart Journal</i> , 2022 , 43, 550-552	9.5	1
114	Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. <i>Heart</i> , 2022 , 108, 61-66	5.1	3
113	Enhancer promoter interactome and Mendelian randomization identify network of druggable vascular genes in coronary artery disease.. <i>Human Genomics</i> , 2022 , 16, 8	6.8	0
112	Understanding gene-lifestyle interaction in obesity: the role of mediation versus moderation.. <i>Lifestyle Genomics</i> , 2022 ,	2	1
111	Mendelian Randomization Analysis Identifies Blood Tyrosine Levels as a Biomarker of Non-Alcoholic Fatty Liver Disease. <i>Metabolites</i> , 2022 , 12, 440	5.6	2
110	Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective. <i>Atherosclerosis</i> , 2022 , 349, 7-16	3.1	16
109	Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. <i>Cell Reports Medicine</i> , 2021 , 2, 100437	18	4
108	Blood Levels of the Hepatokine Are Not Causally Linked with Type 2 Diabetes: A Bidirectional Mendelian Randomization Study.. <i>Nutrients</i> , 2021 , 13,	6.7	1
107	Evaluating Medical Therapy for Calcific Aortic Stenosis: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2354-2376	15.1	3
106	A trans-omic Mendelian randomization study of parental lifespan uncovers novel aging biology and therapeutic candidates for chronic diseases. <i>Aging Cell</i> , 2021 , 20, e13497	9.9	1
105	Polygenic Risk Score for Coronary Artery Disease Improves the Prediction of Early-Onset Myocardial Infarction and Mortality in Men. <i>Circulation Genomic and Precision Medicine</i> , 2021 , CIRCGEN121003452	5.2	0
104	Circulating Galectin-3 Levels Are Not Associated With Nonalcoholic Fatty Liver Disease: A Mendelian Randomization Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3178-e3184	5.6	2
103	System Genetics Including Causal Inference Identify Immune Targets for Coronary Artery Disease and the Lifespan. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003196	5.2	1
102	A Comparative Analysis of the Lipoprotein(a) and Low-Density Lipoprotein Proteomic Profiles Combining Mass Spectrometry and Mendelian Randomization. <i>CJC Open</i> , 2021 , 3, 450-459	2	5
101	Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis. <i>Metabolites</i> , 2021 , 11,	5.6	6
100	Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003271	5.2	2
99	Single-cell expression and Mendelian randomization analyses identify blood genes associated with lifespan and chronic diseases. <i>Communications Biology</i> , 2020 , 3, 206	6.7	5

98	Genetic and In Vitro Inhibition of and Calcific Aortic Valve Stenosis. <i>JACC Basic To Translational Science</i> , 2020 , 5, 649-661	8.7	18
97	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial. <i>JAMA Cardiology</i> , 2020 , 5, 1136-1143	16.2	23
96	Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans. <i>Heart</i> , 2020 , 106, 1407-1412	5.1	3
95	Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Disease-Free Survival, and Mortality Risk: A Mendelian Randomization Analysis. <i>JAMA Network Open</i> , 2020 , 3, e200129	10.4	14
94	Association of FADS1/2 Locus Variants and Polyunsaturated Fatty Acids With Aortic Stenosis. <i>JAMA Cardiology</i> , 2020 , 5, 694-702	16.2	7
93	Dietary sucrose induces metabolic inflammation and atherosclerotic cardiovascular diseases more than dietary fat in LDLrApoB mice. <i>Atherosclerosis</i> , 2020 , 304, 9-21	3.1	8
92	Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. <i>Nature Reviews Endocrinology</i> , 2020 , 16, 177-189	15.2	270
91	Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis. <i>JACC Basic To Translational Science</i> , 2020 , 5, 888-897	8.7	7
90	Acute and Chronic Impact of Biliopancreatic Diversion with Duodenal Switch Surgery on Plasma Lipoprotein(a) Levels in Patients with Severe Obesity. <i>Obesity Surgery</i> , 2020 , 30, 3714-3720	3.7	1
89	A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. <i>Npj Genomic Medicine</i> , 2019 , 4, 23	6.2	45
88	Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification. <i>JAMA Cardiology</i> , 2019 , 4, 620-627	16.2	17
87	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2150-2162	15.1	97
86	Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography. <i>CJC Open</i> , 2019 , 1, 131-140	2	17
85	Acute and chronic effect of bariatric surgery on circulating autotaxin levels. <i>Physiological Reports</i> , 2019 , 7, e14004	2.6	2
84	Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 715-725	18.1	296
83	Genetic Association Analyses Highlight , , and As 3 New Susceptibility Genes Underlying Calcific Aortic Valve Stenosis. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002617	5.2	20
82	Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis. <i>European Heart Journal</i> , 2019 , 40, 1362-1373	9.5	30
81	Saturated Fats from Butter but Not from Cheese Increase HDL-Mediated Cholesterol Efflux Capacity from J774 Macrophages in Men and Women with Abdominal Obesity. <i>Journal of Nutrition</i> , 2018 , 148, 573-580	4.1	9

80	Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1-year randomized study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1740-1750	6.7	5
79	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 130-136	4.9	27
78	LifeB simple 7 and calcific aortic valve stenosis incidence in apparently healthy men and women. <i>International Journal of Cardiology</i> , 2018 , 269, 226-228	3.2	10
77	Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 241-251	15.1	42
76	Soluble CD14 is associated with the structural failure of bioprostheses. <i>Clinica Chimica Acta</i> , 2018 , 485, 173-177	6.2	3
75	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 257-268	6.1	8
74	PCSK9 Involvement in Aortic Valve Calcification. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3225-3227	15.1	21
73	Lipoprotein(a) Is Risky, but What Do We Do About It?. <i>Current Cardiovascular Risk Reports</i> , 2018 , 12, 1	0.9	1
72	Multimarker Approach to Identify Patients With Higher Mortality and Rehospitalization Rate After Surgical Aortic Valve Replacement for Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 2172-2181	15	15
71	Longitudinal Changes in Cholesterol Efflux Capacities in Patients With Coronary Artery Disease Undergoing Lifestyle Modification Therapy. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	3
70	Mortality in the Familial Atherosclerosis Treatment Study-Observational Study. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 309-310	4.9	
69	Cardiovascular disease prevention: lifestyle attenuation of genetic risk. <i>Nature Reviews Cardiology</i> , 2017 , 14, 187-188	14.8	5
68	Does lifestyle contribute to disease severity in patients with inherited lipid disorders?. <i>Current Opinion in Lipidology</i> , 2017 , 28, 177-185	4.4	8
67	OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF- κ B pathway. <i>Cardiovascular Research</i> , 2017 , 113, 1351-1363	9.9	48
66	Acute and Chronic Impact of Bariatric Surgery on Plasma LDL Cholesterol and PCSK9 Levels in Patients With Severe Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 4023-4030	5.6	8
65	Pathobiology of Lp(a) in calcific aortic valve disease. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 797-807	2.5	17
64	Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. <i>Atherosclerosis</i> , 2017 , 263, 137-144	3.1	29
63	Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. <i>Atherosclerosis</i> , 2017 , 256, 47-52	3.1	38

62	Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017 , 37, 43-48	9.4	19
61	Targeting Overconsumption of Sugar-Sweetened Beverages vs. Overall Poor Diet Quality for Cardiometabolic Diseases Risk Prevention: Place Your Bets!. <i>Nutrients</i> , 2017 , 9,	6.7	21
60	Precision Nutrition: A Review of Personalized Nutritional Approaches for the Prevention and Management of Metabolic Syndrome. <i>Nutrients</i> , 2017 , 9,	6.7	177
59	Impact of a 1-year lifestyle modification program on plasma lipoprotein and PCSK9 concentrations in patients with coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1353-1361	4.9	15
58	Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). <i>American Journal of Cardiology</i> , 2016 , 118, 494-8	3	4
57	Circulating Lp-PLA2 is associated with high valvuloarterial impedance and low arterial compliance in patients with aortic valve bioprostheses. <i>Clinica Chimica Acta</i> , 2016 , 455, 20-5	6.2	2
56	Association between plasma lipoprotein levels and bioprosthetic valve structural degeneration. <i>Heart</i> , 2016 , 102, 1915-1921	5.1	19
55	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. <i>Journal of Medical Genetics</i> , 2016 , 53, 835-845	5.8	28
54	Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve. <i>Circulation</i> , 2015 , 132, 677-90	16.7	136
53	Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1286-1295	15.1	46
52	Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1236-1246	15.1	210
51	Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 812-22		42
50	What does the future hold for cholesteryl ester transfer protein inhibition?. <i>Current Opinion in Lipidology</i> , 2015 , 26, 526-35	4.4	1
49	Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 402-404	15.1	31
48	Impact of plasma Lp-PLA2 activity on the progression of aortic stenosis: the PROGRESSA study. <i>JACC: Cardiovascular Imaging</i> , 2015 , 8, 26-33	8.4	41
47	Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). <i>American Journal of Cardiology</i> , 2014 , 113, 1378-82	3	21
46	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 485-94	15.1	372
45	PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program. <i>Atherosclerosis</i> , 2014 , 236, 321-6	3.1	44

44	Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. <i>PLoS ONE</i> , 2014 , 9, e114519	3.7	34
43	Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014 , 34, 457-62	9.4	21
42	Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 304-10		160
41	Clinical and biological relevance of statin-mediated changes in HDL metabolism. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 379	6	0
40	Appreciating the local and systemic effects of exercise training on vascular health. <i>Atherosclerosis</i> , 2013 , 231, 15-7	3.1	1
39	Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. <i>Circulation</i> , 2013 , 128, 1504-12	16.7	135
38	Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 1009-15	4.6	23
37	Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 570-8	4.6	23
36	Mapping body fat distribution: a key step towards the identification of the vulnerable patient?. <i>Annals of Medicine</i> , 2012 , 44, 758-72	1.5	40
35	Normalization of visceral adiposity is required to normalize plasma apolipoprotein B levels in response to a healthy eating/physical activity lifestyle modification program in viscerally obese men. <i>Atherosclerosis</i> , 2012 , 221, 577-82	3.1	18
34	Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1778-84	15.1	51
33	Regression of atherosclerosis. <i>Current Cardiology Reports</i> , 2012 , 14, 443-9	4.2	12
32	The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. <i>Circulation: Cardiovascular Genetics</i> , 2012 , 5, 51-7		17
31	Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 1302-9	27.4	512
30	Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. <i>Circulation</i> , 2012 , 125, 1979-87	16.7	114
29	An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. <i>Future Cardiology</i> , 2012 , 8, 513-31	1.3	11
28	HDL cholesterol is not HDL--don't judge the book by its cover. <i>Nature Reviews Cardiology</i> , 2012 , 9, 557-8	14.8	12
27	PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials. <i>Clinical Lipidology</i> , 2012 , 7, 621-640		14

26	Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 63-9	15.1	30
25	Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. <i>European Heart Journal</i> , 2011 , 32, 336-44	9.5	80
24	Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1535-45	15.1	259
23	Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study). <i>American Journal of Cardiology</i> , 2011 , 108, 367-73	3	32
22	Contributions of cardiorespiratory fitness and visceral adiposity to six-year changes in cardiometabolic risk markers in apparently healthy men and women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1462-8	5.6	33
21	Insulin resistance, low cardiorespiratory fitness, and increased exercise blood pressure: contribution of abdominal obesity. <i>Hypertension</i> , 2011 , 58, 1036-42	8.5	25
20	Lipid parameters for measuring risk of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2011 , 8, 197-206	4.8	144
19	Lipid assessment, metabolic syndrome and coronary heart disease risk. <i>European Journal of Clinical Investigation</i> , 2010 , 40, 1081-93	4.6	24
18	Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size. <i>Clinical Chemistry</i> , 2010 , 56, 789-98	5.5	29
17	The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study. <i>Cmaj</i> , 2010 , 182, 1427-32	3.5	120
16	Age-related differences in the pathogenesis of calcific aortic stenosis: the potential role of resistin. <i>International Journal of Cardiology</i> , 2010 , 142, 126-32	3.2	40
15	Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. <i>International Journal of Cardiology</i> , 2010 , 143, 399-404	3.2	29
14	Oxidized low-density lipoprotein, angiotensin II and increased waist circumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. <i>International Journal of Cardiology</i> , 2010 , 145, 444-9	3.2	32
13	Physical activity, the Framingham risk score and risk of coronary heart disease in men and women of the EPIC-Norfolk study. <i>Atherosclerosis</i> , 2010 , 209, 261-5	3.1	25
12	Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. <i>American Journal of Pathology</i> , 2010 , 176, 2638-45	5.8	57
11	Low cardiorespiratory fitness levels and elevated blood pressure: what is the contribution of visceral adiposity?. <i>Hypertension</i> , 2009 , 54, 91-7	8.5	41
10	Body composition, cardiorespiratory fitness, and low-grade inflammation in middle-aged men and women. <i>American Journal of Cardiology</i> , 2009 , 104, 240-6	3	45
9	Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. <i>Journal of the American College of Cardiology</i> , 2009 , 55, 35-41	15.1	220

8	High-density lipoprotein particle size and concentration and coronary risk. <i>Annals of Internal Medicine</i> , 2009 , 150, 84-93	8	167
7	HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. <i>Atherosclerosis</i> , 2009 , 206, 276-81	3.1	86
6	Effect of exercise training on cardiometabolic risk markers among sedentary, but metabolically healthy overweight or obese post-menopausal women with elevated blood pressure. <i>Atherosclerosis</i> , 2009 , 207, 530-3	3.1	89
5	The concept of cardiometabolic risk: Bridging the fields of diabetology and cardiology. <i>Annals of Medicine</i> , 2008 , 40, 514-23	1.5	62
4	Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, 187-93	9.4	131
3	Examination of encapsulated phytosterol ester supplementation on lipid indices associated with cardiovascular disease. <i>Nutrition</i> , 2007 , 23, 625-33	4.8	26
2	Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. <i>European Heart Journal</i> , 2007 , 28, 2770-7	9.5	44
1	Encapsulated phytosterol ester ingestion positively alters lipid profiles in hypercholesterolemic adults. <i>FASEB Journal</i> , 2007 , 21, A337	0.9	